{"product_id":"mazdutide-10mg-vial","title":"Mazdutide 10mg vial","description":"\u003cp class=\"\" data-end=\"426\" data-start=\"272\"\u003e\u003cspan style=\"color: rgb(255, 42, 0);\"\u003e\u003cstrong\u003e                                            \u003cspan style=\"text-decoration: underline;\"\u003eNOT \u003c\/span\u003e\u003c\/strong\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003eFOR HUMAN \u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan style=\"text-decoration: underline;\"\u003e\u003cspan style=\"color: rgb(255, 42, 0); text-decoration: underline;\"\u003e\u003cstrong\u003eCONSUMPTION\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"426\" data-start=\"272\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"13\" data-start=\"0\"\u003eMazdutide\u003c\/strong\u003e is an investigational, once-weekly injectable peptide developed collaboratively by Innovent Biologics and Eli Lilly.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIt functions as a dual agonist of the \u003cstrong data-end=\"83\" data-start=\"38\"\u003eglucagon-like peptide-1 receptor (GLP-1R)\u003c\/strong\u003e and the \u003cstrong data-end=\"120\" data-start=\"92\"\u003eglucagon receptor (GCGR)\u003c\/strong\u003e.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThis dual mechanism aims to synergistically enhance glycemic control and promote weight loss, positioning mazdutide as a promising therapeutic candidate for \u003cstrong data-end=\"168\" data-start=\"157\"\u003eobesity\u003c\/strong\u003e and \u003cstrong data-end=\"208\" data-start=\"173\"\u003etype 2 diabetes mellitus (T2DM)\u003c\/strong\u003e.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"431\" data-start=\"428\"\u003e\n\u003ch2 class=\"\" data-end=\"462\" data-start=\"433\"\u003e\u003cstrong data-end=\"462\" data-start=\"436\"\u003e2. Mechanism of Action\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"542\" data-start=\"464\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide's dual agonism of GLP-1R and GCGR facilitates multiple metabolic benefits:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"750\" data-start=\"544\"\u003e\n\u003cli class=\"\" data-end=\"647\" data-start=\"544\"\u003e\n\u003cp class=\"\" data-end=\"647\" data-start=\"546\"\u003e\u003cstrong data-end=\"567\" data-start=\"546\"\u003eGLP-1R Activation\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eEnhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"750\" data-start=\"649\"\u003e\n\u003cp class=\"\" data-end=\"750\" data-start=\"651\"\u003e\u003cstrong data-end=\"670\" data-start=\"651\"\u003eGCGR Activation\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIncreases energy expenditure and promotes lipolysis, contributing to weight reduction.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"830\" data-start=\"752\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eBy concurrently targeting these receptors, mazdutide aims to achieve superior metabolic outcomes compared to agents that activate GLP-1R alone.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"835\" data-start=\"832\"\u003e\n\u003ch2 class=\"\" data-end=\"864\" data-start=\"837\"\u003e\u003cstrong data-end=\"864\" data-start=\"840\"\u003e3. Clinical Efficacy\u003c\/strong\u003e\u003c\/h2\u003e\n\u003ch3 class=\"\" data-end=\"923\" data-start=\"866\"\u003e\u003cstrong data-end=\"923\" data-start=\"870\"\u003e3.1. Phase 2 Trial in Overweight and Obese Adults\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1043\" data-start=\"925\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eA randomized, double-blind, placebo-controlled Phase 2 trial evaluated mazdutide's efficacy over 24 weeks in Chinese adults with overweight or obesity.\u003c\/span\u003e \u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"1374\" data-start=\"1045\"\u003e\n\u003cli class=\"\" data-end=\"1143\" data-start=\"1045\"\u003e\n\u003cp class=\"\" data-end=\"1143\" data-start=\"1047\"\u003e\u003cstrong data-end=\"1063\" data-start=\"1047\"\u003eParticipants\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e248 individuals randomized to receive mazdutide (3 mg, 4.5 mg, or 6 mg) or placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1374\" data-start=\"1145\"\u003e\n\u003cp class=\"\" data-end=\"1159\" data-start=\"1147\"\u003e\u003cstrong data-end=\"1158\" data-start=\"1147\"\u003eResults\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"1374\" data-start=\"1162\"\u003e\n\u003cli class=\"\" data-end=\"1203\" data-start=\"1162\"\u003e\n\u003cp class=\"\" data-end=\"1203\" data-start=\"1164\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"18\" data-start=\"0\"\u003eMazdutide 3 mg\u003c\/strong\u003e: Mean weight reduction of 6.7%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1247\" data-start=\"1206\"\u003e\n\u003cp class=\"\" data-end=\"1247\" data-start=\"1208\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"20\" data-start=\"0\"\u003eMazdutide 4.5 mg\u003c\/strong\u003e: Mean weight reduction of 10.4%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1291\" data-start=\"1250\"\u003e\n\u003cp class=\"\" data-end=\"1291\" data-start=\"1252\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"18\" data-start=\"0\"\u003eMazdutide 6 mg\u003c\/strong\u003e: Mean weight reduction of 11.3%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1374\" data-start=\"1294\"\u003e\n\u003cp class=\"\" data-end=\"1374\" data-start=\"1296\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003e\u003cstrong data-is-only-node=\"\" data-end=\"11\" data-start=\"0\"\u003ePlacebo\u003c\/strong\u003e: Mean weight change of +1.0%.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"\" data-end=\"1454\" data-start=\"1376\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eAll mazdutide doses were well tolerated, with gastrointestinal symptoms (e.g., nausea, diarrhea) being the most common adverse events.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"1454\" data-start=\"1376\"\u003e\u003cstrong data-end=\"1490\" data-start=\"1460\"\u003e3.2. Phase 3 GLORY-1 Study\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"\" data-end=\"1610\" data-start=\"1492\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eThe GLORY-1 Phase 3 trial assessed mazdutide's efficacy in weight management among adults with obesity or overweight.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"1754\" data-start=\"1612\"\u003e\n\u003cli class=\"\" data-end=\"1754\" data-start=\"1612\"\u003e\n\u003cp class=\"\" data-end=\"1627\" data-start=\"1614\"\u003e\u003cstrong data-end=\"1626\" data-start=\"1614\"\u003eFindings\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"1754\" data-start=\"1630\"\u003e\n\u003cli class=\"\" data-end=\"1671\" data-start=\"1630\"\u003e\n\u003cp class=\"\" data-end=\"1671\" data-start=\"1632\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSignificant weight loss compared to placebo.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"1754\" data-start=\"1674\"\u003e\n\u003cp class=\"\" data-end=\"1754\" data-start=\"1676\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eReduction in waist circumference and improvement in cardiometabolic risk factors.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 class=\"\" data-end=\"1791\" data-start=\"1756\"\u003e\u003cstrong data-end=\"1791\" data-start=\"1760\"\u003e3.3. Phase 3 DREAMS-2 Study\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"\" data-end=\"1911\" data-start=\"1793\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIn the DREAMS-2 Phase 3 trial, mazdutide was compared to dulaglutide in Chinese patients with T2DM.\u003c\/span\u003e \u003c\/p\u003e\n\u003cul data-end=\"2011\" data-start=\"1913\"\u003e\n\u003cli class=\"\" data-end=\"2011\" data-start=\"1913\"\u003e\n\u003cp class=\"\" data-end=\"1928\" data-start=\"1915\"\u003e\u003cstrong data-end=\"1927\" data-start=\"1915\"\u003eOutcomes\u003c\/strong\u003e:\u003c\/p\u003e\n\u003cul data-end=\"2011\" data-start=\"1931\"\u003e\n\u003cli class=\"\" data-end=\"2011\" data-start=\"1931\"\u003e\n\u003cp class=\"\" data-end=\"2011\" data-start=\"1933\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide demonstrated superior glycemic control and greater weight reduction compared to dulaglutide.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2016\" data-start=\"2013\"\u003e\n\u003ch2 class=\"\" data-end=\"2051\" data-start=\"2018\"\u003e\u003cstrong data-end=\"2051\" data-start=\"2021\"\u003e4. Safety and Tolerability\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"2131\" data-start=\"2053\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eAcross clinical trials, mazdutide has exhibited a favorable safety profile:\u003c\/span\u003e\u003c\/p\u003e\n\u003cul data-end=\"2459\" data-start=\"2133\"\u003e\n\u003cli class=\"\" data-end=\"2240\" data-start=\"2133\"\u003e\n\u003cp class=\"\" data-end=\"2240\" data-start=\"2135\"\u003e\u003cstrong data-end=\"2160\" data-start=\"2135\"\u003eCommon Adverse Events\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eGastrointestinal symptoms such as nausea and diarrhea, generally mild to moderate in severity.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2350\" data-start=\"2242\"\u003e\n\u003cp class=\"\" data-end=\"2350\" data-start=\"2244\"\u003e\u003cstrong data-end=\"2270\" data-start=\"2244\"\u003eSerious Adverse Events\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eNo significant increase in serious adverse events compared to placebo.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10911117\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2459\" data-start=\"2352\"\u003e\n\u003cp class=\"\" data-end=\"2459\" data-start=\"2354\"\u003e\u003cstrong data-end=\"2379\" data-start=\"2354\"\u003eCardiovascular Safety\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eNo notable adverse effects on heart rate or blood pressure.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2464\" data-start=\"2461\"\u003e\n\u003ch2 class=\"\" data-end=\"2492\" data-start=\"2466\"\u003e\u003cstrong data-end=\"2492\" data-start=\"2469\"\u003e5. Pharmacokinetics\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cul data-end=\"2795\" data-start=\"2494\"\u003e\n\u003cli class=\"\" data-end=\"2594\" data-start=\"2494\"\u003e\n\u003cp class=\"\" data-end=\"2594\" data-start=\"2496\"\u003e\u003cstrong data-end=\"2514\" data-start=\"2496\"\u003eAdministration\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSubcutaneous injection once weekly.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2693\" data-start=\"2596\"\u003e\n\u003cp class=\"\" data-end=\"2693\" data-start=\"2598\"\u003e\u003cstrong data-end=\"2611\" data-start=\"2598\"\u003eHalf-life\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eExtended half-life supporting weekly dosing.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"2795\" data-start=\"2695\"\u003e\n\u003cp class=\"\" data-end=\"2795\" data-start=\"2697\"\u003e\u003cstrong data-end=\"2711\" data-start=\"2697\"\u003eMetabolism\u003c\/strong\u003e: \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003ePrimarily degraded by proteolytic enzymes; minimal renal excretion.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003chr class=\"\" data-end=\"2800\" data-start=\"2797\"\u003e\n\u003ch2 class=\"\" data-end=\"2851\" data-start=\"2802\"\u003e\u003cstrong data-end=\"2851\" data-start=\"2805\"\u003e6. Regulatory Status and Future Directions\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3019\" data-start=\"2853\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide is currently undergoing Phase 3 clinical trials for obesity and T2DM.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003ePending successful outcomes, regulatory submissions are anticipated in the near future.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eIts dual receptor activity positions it as a potential alternative to existing GLP-1R agonists, with the added benefit of enhanced weight loss through increased energy expenditure.\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3024\" data-start=\"3021\"\u003e\n\u003ch2 class=\"\" data-end=\"3046\" data-start=\"3026\"\u003e\u003cstrong data-end=\"3046\" data-start=\"3029\"\u003e7. Conclusion\u003c\/strong\u003e\u003c\/h2\u003e\n\u003cp class=\"\" data-end=\"3214\" data-start=\"3048\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eMazdutide represents a novel therapeutic approach targeting both GLP-1 and glucagon receptors to address obesity and T2DM.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eClinical trials have demonstrated its efficacy in weight reduction and glycemic control, with a tolerable safety profile.\u003c\/span\u003e \u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eOngoing Phase 3 studies will further elucidate its potential role in the management of metabolic disorders.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/www.biospace.com\/drug-development\/innovents-lilly-partnered-type-2-diabetes-drug-aces-phase-iii-in-china-inches-closer-to-approval?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003chr class=\"\" data-end=\"3219\" data-start=\"3216\"\u003e\n\u003cp class=\"\" data-end=\"3236\" data-start=\"3221\"\u003e\u003cstrong data-end=\"3235\" data-start=\"3221\"\u003eReferences\u003c\/strong\u003e:\u003c\/p\u003e\n\u003col data-end=\"3623\" data-start=\"3238\"\u003e\n\u003cli class=\"\" data-end=\"3365\" data-start=\"3238\"\u003e\n\u003cp class=\"\" data-end=\"3365\" data-start=\"3241\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eSafety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled, phase 2 trial. \u003cem data-end=\"217\" data-start=\"194\"\u003eNature Communications\u003c\/em\u003e.\u003c\/span\u003e\u003cspan class=\"ms-1 inline-flex max-w-full items-center relative top-[-0.094rem] animate-[show_150ms_ease-in]\"\u003e\u003ca class=\"flex h-4.5 overflow-hidden rounded-xl px-2 text-[0.5625em] font-medium text-token-text-secondary! bg-[#F4F4F4]! dark:bg-[#303030]! transition-colors duration-150 ease-in-out\" rel=\"noopener\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10719339\/?utm_source=chatgpt.com\" target=\"_blank\"\u003e\u003cspan class=\"relative start-0 bottom-0 flex h-full w-full items-center\"\u003e\u003cspan class=\"flex h-4 w-full items-center justify-between absolute\"\u003e\u003cspan class=\"-me-1 flex h-full items-center rounded-full px-1 text-[#8F8F8F]\"\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/a\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3494\" data-start=\"3367\"\u003e\n\u003cp class=\"\" data-end=\"3494\" data-start=\"3370\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eInnovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions. \u003cem data-end=\"144\" data-start=\"131\"\u003ePR Newswire\u003c\/em\u003e.\u003c\/span\u003e \u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"\" data-end=\"3623\" data-start=\"3496\"\u003e\n\u003cp class=\"\" data-end=\"3623\" data-start=\"3499\"\u003e\u003cspan class=\"relative -mx-px my-[-0.2rem] rounded px-px py-[0.2rem] transition-colors duration-100 ease-in-out\"\u003eInnovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes Were Orally Presented at EASD 2024. \u003cem data-end=\"146\" data-start=\"133\"\u003ePR Newswire\u003c\/em\u003e.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"RCpeptides","offers":[{"title":"Default Title","offer_id":52684859900242,"sku":null,"price":80.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1048\/0956\/2450\/files\/mazdutide_10mg.png?v=1770834901","url":"https:\/\/sciencepeptideslab.com\/products\/mazdutide-10mg-vial","provider":"Science Peptides Lab","version":"1.0","type":"link"}